Developing a new treatment for Alzheimer's disease using EP2 receptor antagonists
Official title: Development of EP2 Receptor Antagonist to Treat Alzheimer's Disease
Funded at Emory University · NIH-10944958 · Data updated 2026-11-12
This study is testing a new medication that could help people with Alzheimer's by reducing brain inflammation and amyloid buildup, which may help keep their thinking skills sharper.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | September 20, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $1,737,244 |
| NIH project number | 1U01AG088113-01 |
| Project ID | NIH-10944958 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those showing early signs of cognitive decline.
✕Less likely to help
Patients with other types of dementia or cognitive impairments unrelated to Alzheimer's disease may not benefit from this research.
What this research studies
This research focuses on creating a new type of medication aimed at treating Alzheimer's disease by targeting the EP2 receptor, which plays a significant role in neuroinflammation associated with the disease. The approach involves developing small-molecule antagonists that can block this receptor, potentially reducing inflammation and amyloid buildup in the brain. The research has shown promising results in animal models, indicating that this treatment could help preserve cognitive function in patients. By validating this novel mechanism, the study aims to provide a new therapeutic option for those affected by Alzheimer's.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that slows the progression of Alzheimer's disease and improves cognitive function in patients.
How similar studies have gone: Previous research has shown success with similar approaches targeting neuroinflammation in Alzheimer's, but this specific mechanism is relatively novel.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Ganesh, Thota — Emory University
- Study coordinator: Ganesh, Thota
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.